Other News To Note

• Camargo Pharmaceutical Services, of Cincinnati, said it completed five pre-investigational new drug meetings last month with the FDA for 505(b)(2) products, including two for India-based pharmaceutical companies. Since 505(b)(2) drugs rely in part on data from already approved therapies, they can be developed and get FDA approval in as little as 30 months with fewer trials and at a lower cost.